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Safe parenteral nutrition 
and the role of standardised 
feeds
ABSTRACT
Workload pressure on pharmacies through increased demands for parenteral nutrition (PN) is leading to a growing trend 
in the use of commercially manufactured PN (‘standard feeds’) and away from individually ‘tailored’ prescriptions. This is 
sometimes justified on grounds of safety, although many areas of risk remain inherent in the process of PN provision. In fact 
there is little to suggest that widespread introduction of standard feeds would do much to further reduce the already low 
frequency of serious adverse events. The relative clinical benefits of providing standard feeds or tailored feeds have not 
been adequately studied, making it impossible to give a clear endorsement of one system over the other. It seems probable 
that for a proportion of stable patients a range of standard feeds could provide adequate nutritional support, while in unsta-
ble patients with complex needs and those needing long term PN, tailored feeds appear the more logical choice. Pharmacy 
compounding units, therefore, need to remain flexible in their approach to PN provision. Since even small variations in 
nutrient intake in early life may have long lasting implications for extremely premature infants the processes of formulating 
and providing PN deserve further study.
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Introduction
Parenteral nutrition (PN) as a life saving 
intervention in children was first des-
cribed forty years ago by Wilmore and 
Dudrick in an infant with small bowel 
atresia. (1) Since then it has become 
widely used for children in whom nutri-
tional requirements cannot be met via 
the gastrointestinal tract. Although in 
the child with complex intestinal failure 
the benefits of PN are unquestiona-
ble (e.g. short bowel syndrome), other 
indications such as premature birth are 
less well defined. Despite this fact, the 
premature newborns now comprise 
one of the largest patient groups to 
be given PN. (2)  Potential advantages 
of achieving better nutritional support 
have to be weighed against the risk of 
complications. In the early years of PN 
ring light protection and in-line filtration. 
Greater use of standardised feeds (also 
known as ’premixed PN solution’ or 
’commercial PN product’) bought in 
’ready made’ from industrial suppliers, 
and a reduced reliance on manufacture 
in hospital pharmacies may be one way 
of reducing the risk of adverse events. 
Commercial supply brings with it the 
reassurance of the feed having been 
end product tested (although additions 
such as electrolytes must still be made), 
something that is not easily achievable 
in a hospital pharmacy making up indi-
vidualised feed prescriptions on a daily 
basis. Pressure to move away from indi-
vidualised PN prescriptions comes not 
only from safety concerns but also as a 
response to rising demand and need to 
manage pharmacy workload. Safety is 
rightly a major concern of the clinician, 
but so too is how to provide the most 
effective nutritional support for any 
individual patient.  In this respect, the 
these included serious metabolic dis-
turbance such as lactic acidosis (3) and 
encephalopathy. (4) With accumulating 
clinical experience PN has become 
safer, but major risks remain, including 
catheter related blood stream infecti-
on, (5) intestinal failure associated liver 
disease (6) and venous thrombosis. (7) 
The positive effects of a multidiscipli-
nary nutrition support team in reducing 
the rate of such complications are well 
recognised. (8) 
Other risks lie in the process of pro-
viding PN. Adverse events may result 
from errors in transcription of pres-
criptions, compounding and admini-
stration. For example, inappropriate 
use (therapeutic risk leading to patient 
harm), mistakes in diluting concentra-
ted components, complex calculations 
and manipulations in pharmacy, recon-
stitution of powders in vials, the need 
for pumps and syringe drivers, and the 
use of non-standard giving sets requi-
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relative clinical merits of standardised 
versus individualised PN prescriptions 
have been little studied. While recent 
European guidelines for PN assert that: 
“uncritical use of standard formulati-
ons particularly over a longer period of 
time may be detrimental to growth and 
development” (9) there are no good 
randomised trials to support this expert 
opinion based statement. To evaluate 
safety implications further it is neces-
sary to consider where errors do occur 
in the PN process.
Where do errors in the PN 
process arise and how 
might they be mitigated?
Kuiper et al. (10) reflected on medicati-
on errors in general in inpatient pharma-
cy operations and what might be done 
to bring about improvements in safety. 
They pointed out that the inpatient 
pharmacy component of the medica-
tion-use process is complex and error 
prone, relying on interactions among 
providers, patients, information and 
technology.  The pharmacists interpret 
and transcribe prescriptions, prepare 
them and ensure delivery. Drug pre-
paration and dispensation have been 
implicated in 11-21% of all medication 
errors. PN solutions are complex, con-
taining almost 50 ingredients prepared 
by the mixing of more than 10 diffe-
rent solutions. Successful technologies 
reduce the potential for human error 
by automating tasks that require high 
levels of accuracy and repetition. A 
microprocessor-controlled compoun-
ding device is an example of such equ-
ipment. (11) Risk management strate-
gies remain a fundamentally important 
adjunct to any such innovation and 
might, for example, include supervising 
and regularly performing aseptic vali-
dations of pharmacy staff, monitoring 
for microbial contamination, regular 
audits, providing standard operating 
procedures, and enforcing an agreed 
capacity plan (matching needs to abili-
ties) when necessary. (10)
Sacks et al. (12) explored how often 
medication errors occurred in relation 
to PN, as well as the harm that resulted 
and where in the PN process errors 
arose. The setting was a large teaching 
hospital caring for both children and 
adults; a prospective study was carried 
out over a seven month period. A total of 
4730 prescriptions for PN were made in 
the course of the study; 74 (1.6%) were 
associated with a medication error. Of 
these errors, 1 (1%) occurred during the 
prescription process and was detected 
before preparation; 29 (39%) occurred 
during the transcription process, 18 
(24%) during preparation, and 26 (35%) 
during the administration process. Sixty 
seven (91%) of the errors were consi-
dered as non-harmful whereas 6 (8%) 
contributed to or resulted in harm to a 
patient. The rate of errors (15.6/1000 
PN days) was similar to that observed in 
the same institution with ’high risk’ drug 
prescriptions. The authors concluded 
that errors in the PN process regularly 
occur and occasionally result in harm, 
emphasising the need to follow good 
practice guidelines. 
The use of systematic risk analysis 
methods may be an additional way 
of improving safety in PN production. 
Bonnabry and colleagues (13) write 
about this approach in their institution 
where the preparation of paediatric PN 
included re-transcription and manual 
compounding of the mixture. Chan-
ges to reduce risk were introduced and 
included new prescription software, 
direct recording on a server, automatic 
printing of the labels and piloting of 
an automatic compounder. They then 
employed a ’failure modes, effects, and 
criticality analysis’ (FMECA) technique 
to explore how the safety of the PN 
process might be improved. FMECA 
assesses systematically a process or 
product and enables determination of 
the location and mechanism of poten-
tial failures. A given process is bro-
ken down in order to identify possible 
or likely errors, and gauge what their 
effect will be, even before they take 
place. In addition, there is a quantifi-
cation of failures by a ’criticality index’ 
(CI) that is calculated by taking into 
account scores for likelihood of occu-
rrence, severity of the potential effect 
and chance of detecting the error. The 
pharmacy team considered ’what could 
possibly go wrong with this process 
step?’ and CI was compared between 
the old and new systems. The new 
process reduced total CI by 59%. The 
highest risks in the old process were 
computed for dosage errors, product 
exchange, failure to detect a dosage/
product error, and product omission. 
In the new process the most critical 
steps were labelling mistakes, failure 
to detect a dosage/product mistake, 
failure to detect a typing error during 
prescription, and microbial contami-
nation. The new process significantly 
increased safety by reducing the risk in 
administering a solution with a dosage 
error. The largest improvement in safety 
was obtained by elimination of fax tran-
smission and re-transcription, and by 
automation of the compounding proce-
dure. The authors advocate proactive 
risk analysis methods such as FMECA 
for improving the safety of high risk pro-
cesses, especially when it is difficult to 
directly measure an outcome because 
of its very low incidence.
Individualised and standar-
dised feeds for PN
Given the heterogeneous nature of 
patients receiving PN, the possibility 
of individualising prescriptions taking 
into account not just age and weight, 
but variable fluid and electrolyte requ-
irements, partial enteral feeding and 
additional intravenous fluids seems 
attractive. Ball et al. (14) described a 
novel computer assisted prescribing 
system that could be taken to the bed-
side and used to come up with a nutri-
tional prescription based on all these 
factors for each patient. It also included 
built in safety checks, for example if 
nutrient intakes were ordered outside 
set parameters. There are a number of 
assumptions implicit in the use of such 
systems: that the pharmacy aseptic 
compounding unit has the capacity to 
make up individualised feeds on a daily 
basis, and that this process is likely to 
yield clinical benefits compared with 
using a less flexible standardised feed. 
It is clear that the first assumption is 
likely to be challenged in periods of 
increased demand, and the second 
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has not been adequately tested, altho-
ugh some of the relevant literature is 
discussed below. 
Since most PN is provided on a short 
term basis (for example 1 – 2 weeks in 
the preterm infant) measuring relevant 
clinical outcomes is difficult and imme-
diately makes comparison of different 
feeding systems problematical. Cade 
et al. (15) randomly allocated 52 con-
secutive preterm infants admitted to a 
large teaching hospital neonatal inten-
sive care unit (NICU) to either standard 
PN feed (with flexible electrolyte addi-
tion) or individualised feed formulated 
using the computer program originally 
developed by Ball. (14)  The hypot-
hesis of the study was that compu-
ter-assisted prescribing through taking 
into account the nutritional composition 
of supplementary fluids would redu-
ce PN feed waste, improve electrolyte 
balance, and promote growth when 
compared with the standardised feed 
approach. In fact, no differences were 
found between the two groups. The aut-
hors concluded that the considerable 
flexibility afforded by computer assisted 
prescribing may be of little benefit to 
most patients, while not discounting 
the possibility of it conferring advantage 
in some (e.g. those with unusual fluid 
and nutrient requirements or during 
prolonged PN). The same group went 
on to look in detail at what actually hap-
pened when using computer assisted 
prescribing for patients on the NICU, 
in terms of how often deviations from 
a standard feed composition occurred, 
and whether it was plausible that such 
deviations were of clinical significance. 
(16) In all, 148 prescriptions were exa-
mined and nutrient content compared 
with a standard formulation (i.e. regi-
men based on age and size assuming 
normal fluid, electrolyte and nutrient 
requirements). One fifth of the feeds 
conformed completely to the standard 
regimen, while 80% showed some devi-
ation. These deviations were, however, 
mainly in relation to carbohydrate, sodi-
um and phosphate intake and actually 
reflected a routine practice on this par-
ticular NICU that was at variance with 
the computer PN regimens. In other 
words, if this practice was incorporated 
within a standardised PN prescripti-
on, around two thirds of patients might 
have received almost identical nutrient 
intakes whether by individualised com-
puter assisted prescribing or by use of 
a standardised feed.
In another investigation of preterm 
infants <33 weeks gestation, standar-
dised versus individualised feeds were 
compared with respect to nutrient inta-
kes achieved and biochemical respon-
ses. (17) Two commercially produced 
standardised PN formulations were 
used in the study, which included 58 
patients. The composition of the indivi-
dualised PN formulations was determi-
ned each morning at the discretion of 
the attending neonatologist based on 
a prescribing guideline and current bio-
chemistry results. The two study groups 
were clinically matched; there were no 
significant differences in biochemical 
responses; the standardised PN group 
received 42% more amino acids during 
the first week of life, and 25% more 
calcium and phosphate than the indi-
vidualised PN patients.  PN acquisition 
cost was estimated to be 30% less with 
the standardised system. 
Lenclen and colleagues (18) changed 
from individualised to standard PN 
feeds on their NICU and retrospectively 
compared 40 infants <32 weeks gesta-
tional age with respect to nutrient intake 
and plasma biochemistry. They found 
that a 20% higher amino acid intake 
was achieved over the fist week in the 
standardised group who were also less 
likely to need insulin infusions and more 
likely to have better calcium and phosp-
hate intakes. Similar advantage has 
been suggested in using standardised 
PN formulations for paediatric intensive 
care patients (19) where calcium and 
phosphate intakes were lower and elec-
trolyte imbalance more common when 
using individualised prescriptions.
A recent study by Eleni-dit-Trolli and 
colleagues (20) has suggested that 
clinical benefits may be derived from 
early individualised parenteral nutrition 
prescribing. Once again this was a 
retrospective study following a change 
in unit prescribing practice, in a relati-
vely small group of 40 preterm infants 
<28 weeks gestation. The compari-
son is not between individualised and 
standardised feeds, but between two 
methods of arriving at an individuali-
sed prescription. With the new method 
applied, the parenteral intake was cal-
culated using spreadsheet software 
which took into account the desired 
fluid and nutrient intake, the nutrition 
provided by partial enteral feeding, 
and the volume of drugs prescribed. 
This appears to be a more sophistica-
ted approach to PN prescribing than 
the earlier method used on this unit, 
although no details of the latter are 
provided other than the statement “all 
individualised PN orders were calcula-
ted at the bedside”. Whatever changes 
were actually made, the results indica-
ted an improvement in amino acid and 
energy intake achieved, shorter time to 
regain birth weight, and lower risk of 
severe broncho-pulmonary dysplasia. 
It is difficult to know how to interpret this 
study, although it does suggest that 
fine tuning of PN in individual patients 
leading to quite small differences in 
nutrient intake, may have measurable 
clinical benefit. This could in fact be 
highly relevant to long term outcomes 
given such investigations as the Bonn 
longitudinal study of very low birthwe-
ight small for gestational age infants 
that indicated an effect of energy inta-
ke in only the first ten days of life on 
brain growth and mental development 
persisting through to adulthood. (21) 
Similarly, minor differences in enteral 
feeding of preterm infants in the first 
few weeks of life have also been shown 
to exert a striking long term effect. (22)
Conclusions
The complexities of providing PN mean 
that adverse events will sometimes 
occur. Compounding errors are rare, 
although clinical consequences may be 
serious, including risk of death. There 
are many ways of reducing risk such 
as following best practice guidelines, 
avoiding unnecessary transcription of 
prescriptions, using automated com-
pounding machines, and regularly 
auditing activity including performing 
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proactive risk analysis. The impact of 
end product tested commercial stan-
dardised feeds on safety is likely to be 
small, and does not provide a powerful 
argument in favour of their use. There 
may be cost savings involved in the use 
of standardised feeds, but on this point 
the literature contains conflicting data 
(23) and an assessment from industry 
is that costs are not likely to be lowered 
and may in fact be increased. (24)
It is almost certainly the case that a 
proportion of patients can be mana-
ged perfectly well in terms of nutritional 
outcomes with a range of standardised 
feeds. These would most probably be 
patients without complex fluid, electrol-
yte and nutrient requirements and nee-
ding only short term PN. The proportion 
of such patients (as opposed to those 
needing individualised feeds in order 
to provide optimal achievable nutrient 
intakes) will vary according to the type 
of hospital institution and complexity 
of case mix. The evidence that a PN 
process involving only use of standar-
dised feeds will produce equivalent 
clinical outcomes to individualised feed 
prescription is lacking. This may be 
particularly important in the preterm 
newborn infant where the effects of 
relatively small differences in nutrient 
intake over the early days of life might 
only be measurable in terms of long 
term outcomes rather than short term 
growth and biochemical monitoring. 
This underlines both the importance of 
adequately powered nutritional studi-
es with long term outcome measures, 
and the ability of hospital compounding 
units to maintain flexibility with respect 
to the PN process. This will ensure that 
standardised feeds are used for those 
patients who can be effectively mana-
ged in this way, while the flexibility of 
individualised PN prescribing will still 
be necessary for others in order to best 
meet their nutritional needs.
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